Microbeads: A Green Alternative -TerraVerdae BioWorks gears up for production using a proprietary process that successfully produces non-petroleum-based plastics that safely biodegrade.
Quad Technologies Inc (“Quad”), developer of a novel cell separation technology, has secured a substantial amount of capital from its Series A round to accelerate development of disruptive cell processing technologies for translational medicine applications. The investment has enabled Quad to launch its MagCloudz™ Streptavidin Cell Separation Kit, which is the first commercially available product incorporating its proprietary QuickGel™ technology.
Arkrivis Technologies has announced that it was awarded by the National Cancer Institute (NCI) its second Phase I SBIR Contract.
The Boston Business Journal reports on the important issue of bridging the gap between academia and biotechnology businesses in a two-part series on the EurekaConnect event held September 24th and 25th in Boston. Dr. Martha Farmer, CEO and President of NSIV, was a participant.
Biotech Startups Struggle to Find Space in Kendall Square
Here’s how NSIV members completed this phrase: “You know you’re an entrepreneur IF….”
Investing in the State of Innovation Massachusetts Life Sciences Center Board Approves New Round of Accelerator Program Loans Windgap Medical Is an NSIV Graduate
We were delighted to welcome back two NSIV graduates for November’s InnoVentures U program, “Life Beyond NSIV.” Joel Berniac of Akrivis Technologies and Scott Sneddon of Sharp Edge Labs are shining examples of entrepreneurs who have made a successful transition from the NSIV incubator to their new roles as company spokesmen. Special thanks to NSIV Chairman Harry McCoy for moderating this panel discussion.
Congratulations to cleantech member Founder & CEO William Bardosh and his company TerraVerdae BioWorks, who has been chosen to participate in the Young Entrepreneurs Initiative (YEi) Program.